JP2024516363A - リボシクリブ及びアムセネストラントを含む組み合わせ - Google Patents
リボシクリブ及びアムセネストラントを含む組み合わせ Download PDFInfo
- Publication number
- JP2024516363A JP2024516363A JP2023562511A JP2023562511A JP2024516363A JP 2024516363 A JP2024516363 A JP 2024516363A JP 2023562511 A JP2023562511 A JP 2023562511A JP 2023562511 A JP2023562511 A JP 2023562511A JP 2024516363 A JP2024516363 A JP 2024516363A
- Authority
- JP
- Japan
- Prior art keywords
- ribociclib
- pharma
- acceptable salt
- amsenestrant
- ceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21315064 | 2021-04-12 | ||
| EP21315064.2 | 2021-04-12 | ||
| PCT/EP2022/059700 WO2022218956A1 (en) | 2021-04-12 | 2022-04-12 | Combination comprising ribociclib and amcenestrant |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024516363A true JP2024516363A (ja) | 2024-04-15 |
| JP2024516363A5 JP2024516363A5 (cg-RX-API-DMAC7.html) | 2025-04-16 |
Family
ID=75825774
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023562511A Pending JP2024516363A (ja) | 2021-04-12 | 2022-04-12 | リボシクリブ及びアムセネストラントを含む組み合わせ |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20240197739A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4322941A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024516363A (cg-RX-API-DMAC7.html) |
| CN (1) | CN117136053A (cg-RX-API-DMAC7.html) |
| AR (1) | AR125331A1 (cg-RX-API-DMAC7.html) |
| TW (1) | TW202304425A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022218956A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3847157T3 (da) | 2018-09-07 | 2022-08-08 | Sanofi Sa | Fremgangsmåde til fremstilling af methyl-[6-(2,4-dichlorphenyl)-5-[4-[(3s)-1-(3-fluorpropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulen-2-carboxylat] og salt deraf |
| WO2021063967A1 (en) | 2019-10-01 | 2021-04-08 | Sanofi | Novel substituted 6,7-dihydro-5h-benzo[7]annulene compounds, processes for their preparation and therapeutic uses thereof |
| CA3160897A1 (en) | 2019-12-09 | 2021-06-17 | Sanofi | Crystalline form of a 7h-benzo[7]annulene-2-carboxylic acid derivative |
| TW202146007A (zh) | 2020-02-27 | 2021-12-16 | 法商賽諾菲公司 | 包含阿培利司(alpelisib)與6-(2,4-二氯苯基)-5-[4-[(3s)-1-(3-氟丙基)吡咯啶-3-基]氧苯基]-8,9-二氫-7h-苯并[7]輪烯-2-羧酸之組合 |
| IL302153B1 (en) | 2020-10-19 | 2026-07-01 | Sanofi Sa | 6,7-DIHYDRO-5H-BENZO[7]ANNULENE COMPOUNDS AND THEIR DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR THERAPEUTIC USES |
| IL302152B1 (en) | 2020-10-19 | 2026-07-01 | Sanofi Sa | 6,7-DIHYDRO-5H-BENZO[7]ANNULENE COMPOUNDS AND THEIR DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR THERAPEUTIC USES |
| WO2025085738A1 (en) | 2023-10-18 | 2025-04-24 | Halda Therapeutics Opco, Inc. | Heterobifunctional compounds and methods of treating disease |
| WO2025189056A1 (en) | 2024-03-08 | 2025-09-12 | Halda Therapeutics Opco, Inc. | Heterobifunctional compounds and their use in treating disease |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2016528246A (ja) * | 2013-08-14 | 2016-09-15 | ノバルティス アーゲー | がんの治療のための組合せ療法 |
| JP2018537406A (ja) * | 2016-02-15 | 2018-12-20 | サノフイSanofi | エストロゲン受容体調節剤としての6,7−ジヒドロ−5h−ベンゾ[7]アヌレン誘導体 |
| WO2019020559A1 (en) * | 2017-07-24 | 2019-01-31 | Sanofi | COMBINATION COMPRISING PALBOCICLIB AND 6- (2,4-DICHLOROPHENYL) -5- [4 - [(3S) -1- (3-FLUOROPROPYL) PYRROLIDIN-3-YL] OXYPHENYL] -8,9-DIHYDRO ACID -7H-BENZO [7] ANNULENE-2-CARBOXYLIC AND ITS USE FOR THE TREATMENT OF CANCER |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2022010425A (es) * | 2020-03-06 | 2022-09-07 | Olema Pharmaceuticals Inc | Metodos de tratamiento de enfermedades asociadas a los receptores de estrogenos. |
-
2022
- 2022-04-08 TW TW111113411A patent/TW202304425A/zh unknown
- 2022-04-11 AR ARP220100915A patent/AR125331A1/es not_active Application Discontinuation
- 2022-04-12 JP JP2023562511A patent/JP2024516363A/ja active Pending
- 2022-04-12 US US18/286,510 patent/US20240197739A1/en active Pending
- 2022-04-12 CN CN202280028202.XA patent/CN117136053A/zh active Pending
- 2022-04-12 WO PCT/EP2022/059700 patent/WO2022218956A1/en not_active Ceased
- 2022-04-12 EP EP22718731.7A patent/EP4322941A1/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2016528246A (ja) * | 2013-08-14 | 2016-09-15 | ノバルティス アーゲー | がんの治療のための組合せ療法 |
| JP2018537406A (ja) * | 2016-02-15 | 2018-12-20 | サノフイSanofi | エストロゲン受容体調節剤としての6,7−ジヒドロ−5h−ベンゾ[7]アヌレン誘導体 |
| WO2019020559A1 (en) * | 2017-07-24 | 2019-01-31 | Sanofi | COMBINATION COMPRISING PALBOCICLIB AND 6- (2,4-DICHLOROPHENYL) -5- [4 - [(3S) -1- (3-FLUOROPROPYL) PYRROLIDIN-3-YL] OXYPHENYL] -8,9-DIHYDRO ACID -7H-BENZO [7] ANNULENE-2-CARBOXYLIC AND ITS USE FOR THE TREATMENT OF CANCER |
Non-Patent Citations (3)
| Title |
|---|
| BESRET, LAURENT ET AL.: "Translational strategy using multiple nuclear imaging biomarkers to evaluate target engagement and e", EJNMMI RESEARCH, vol. 10, no. 1, JPN6026016719, 2020, ISSN: 0005856109 * |
| MASSARWEH, SULEIMAN ET AL.: "A phase II study of combined fulvestrant and everolimus in patients with metastatic estrogen recepto", BREAST CANCER RESEARCH AND TREATMENT, vol. 143, no. 2, JPN6026016721, 2013, pages 325 - 332, ISSN: 0005856111 * |
| SLAMON, DENNIS J. ET AL.: "Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epiderm", JOURNAL OF CLINICAL ONCOLOGY, vol. 36, no. 24, JPN6026016720, 2018, pages 2465 - 2472, ISSN: 0005856110 * |
Also Published As
| Publication number | Publication date |
|---|---|
| AR125331A1 (es) | 2023-07-05 |
| EP4322941A1 (en) | 2024-02-21 |
| TW202304425A (zh) | 2023-02-01 |
| CN117136053A (zh) | 2023-11-28 |
| US20240197739A1 (en) | 2024-06-20 |
| WO2022218956A1 (en) | 2022-10-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240197739A1 (en) | Combination Comprising Ribociclib and Amcenestrant | |
| EP4110326B1 (en) | Combination comprising alpelisib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid | |
| JP2023550149A (ja) | アベマシクリブと6-(2,4-ジクロロフェニル)-5-[4-[(3s)-1-(3-フルオロプロピル)ピロリジン-3-イル]オキシフェニル]-8,9-ジヒドロ-7h-ベンゾ[7]アヌレン-2-カルボン酸とを含む組み合わせ | |
| ES3036485T3 (en) | Combination comprising everolimus and amcenestrant | |
| TWI922768B (zh) | 包含cdk4抑制劑之用於治療癌症之方法及給藥方案 | |
| AU2018234903B2 (en) | Combination therapies for the treatment of breast cancer | |
| TW202539669A (zh) | 雌激素受體降解劑之給藥方案 | |
| AU2020381240C1 (en) | Therapeutic combinations of acalabrutinib and capivasertib to treat B-cell malignancies | |
| US10085996B2 (en) | Pharmaceutical combinations | |
| HK40110657A (en) | Cdk4 inhibitor for the treatment of cancer | |
| EA045670B1 (ru) | Терапевтические комбинации акалабрутиниба и капивасертиба для лечения в-клеточных злокачественных образований |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250408 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20250408 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20260512 |